SCHEMBL30007738

SCHEMBL30007738

CC(C)S(=O)(=O)c1ccc(-c2cnc3[nH]nc(C(=O)N4CCC(c5ccccc5)CC4)c3c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
SCD5 Q86SK9 7/20 0.40
SCD O00767 3/20 0.40
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
KCNH2 Q12809 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30007560 0.91 CA12 (0.43) KDM5ACA12CA1CA2CA7
SCHEMBL30007554 0.85 AVPR1A (0.47) CA12CA1CA2CA7CA9
SCHEMBL30007902 0.79 GSK3A (0.46) GSK3AGSK3BPRKAB2PRKAG1PRKAA2
SCHEMBL30007369 0.75 DRD2 (0.47) ALDH1A1
SCHEMBL30007830 0.75 DYRK1A (0.45) GSK3AGSK3BLMNAMAPTROCK2
SCHEMBL30007265 0.75 AVPR1A (0.49) CA12CA1CA2CA7CA9
SCHEMBL30007741 0.72 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL30007804 0.70 ALDH1A1 (0.46) ALDH1A1
SCHEMBL29253947 0.69 GSK3A (0.48) GSK3AGSK3B
SCHEMBL30007692 0.68 GSK3A (0.51) GSK3AGSK3BKCNH2PRKAG1PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022237922-A1 ANTITUMOR COMPOUNDS BASED ON NITROGEN HETEROCYCLES AND USE THEREOF AS MEDICAMENTS FAKULTNI NEMOCNICE HRADEC KRALOVE (CZ) 2022-11-17 WO disclosed